25 Mar 2021
DeepVerge PLC
("DeepVerge" or "Company")
DeepVerge Investor Presentation
Project Updates on Labskin, Modern Water, Skin Trust Club and Microsaic Agreement
DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces that, DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces that, is pleased to announce that Gerry Brandon, CEO will provide a live presentation relating to Project Updates - Labskin, Skin Trust Club, Modern Water - Wastewater & Breath Test via the Investor Meet Company platform on 31st Mar 2021 at 1:30pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet DEEPVERGE PLC via:
https://www.investormeetcompany.com/deepverge-plc/register-investor
Investors who already follow DEEPVERGE PLC on the Investor Meet Company platform will automatically be invited.
|
DeepVerge plc |
Gerry Brandon |
+44 (0) 734 0055 648 |
|
|
|
|
|
SPARK Advisory Partners Limited (Nominated Adviser) |
Neil Baldwin/Andrew Emmott |
+44 (0) 113 370 8974 |
|
|
|
|
|
Turner Pope Investments (TPI) Limited (Broker) |
Andy Thacker/Zoe Alexander |
+44 (0) 20 3657 0050 |
About DeepVerge plc (www.deepverge.com)
DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments and the data they generate, for the analysis and identification of bacteria, virus and toxins. DeepVerge is utilising artificial intelligent data analytics to prove scientifically the impact of skincare product claims on the skin microbiome for clients including most of the top 20 global cosmetic companies and to detect remotely, and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.
About Microsaic (www.microsaic.com)
Microsaic floated on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested c.£30m over 20 years of development, Microsaic has a robust and innovative patent portfolio in cutting-edge technology designed and developed for "Industry 4.0" application. Microsaic serves markets in Human Health, Environmental Health and Diversified Industries. Microsaic's system solutions enable analytical detection and characterisation at the point-of-need, whether within a conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection data at multiple steps in the process workflow.
Microsaic's products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point of need applications.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.